Hong Kong Stocks Movement | VIGONVITA-B (02630) Surges Over 15% in Afternoon Trading After Licensing Agreement with SIMCERE PHARMA for VV116 New Indications

Stock News12-17

VIGONVITA-B (02630) surged more than 15% in afternoon trading, rising 14.81% to HK$88 by the time of writing, with a turnover of HK$13.33 million. The company recently announced a licensing agreement with SIMCERE PHARMA (02096) for new indications of VV116. Under the agreement, SIMCERE PHARMA will obtain exclusive licensing rights for deuterium remdesivir hydrobromide dry suspension in Greater China for treating respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections. The collaboration leverages the strengths of both companies in R&D, production, and commercialization to accelerate the clinical development and commercialization of VV116, aiming to benefit more patients. Public data shows that VIGONVITA-B focuses on three therapeutic areas: neuropsychiatry, reproductive health, and viral infections. As of October 21, 2025, the company has established a diversified pipeline of nine innovative drugs, with two in commercialization, four in clinical stages, and three in preclinical stages. In addition to its innovative drug pipeline, the company also has a generic drug segment, with three drugs in or nearing commercialization. Currently, VIGONVITA-B's two core products are LV232 and TPN171.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183973139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 13:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183973139","market":"hk","top_or_hot":-1,"title":"Hong Kong Stocks Movement | VIGONVITA-B (02630) Surges Over 15% in Afternoon Trading After Licensing Agreement with SIMCERE PHARMA for VV116 New Indications","media":"Stock News","content":"<p>VIGONVITA-B (02630) surged more than 15% in afternoon trading, rising 14.81% to HK$88 by the time of writing, with a turnover of HK$13.33 million. The company recently announced a licensing agreement with SIMCERE PHARMA (02096) for new indications of VV116. Under the agreement, SIMCERE PHARMA will obtain exclusive licensing rights for deuterium remdesivir hydrobromide dry suspension in Greater China for treating respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections. The collaboration leverages the strengths of both companies in R&D, production, and commercialization to accelerate the clinical development and commercialization of VV116, aiming to benefit more patients. Public data shows that VIGONVITA-B focuses on three therapeutic areas: neuropsychiatry, reproductive health, and viral infections. As of October 21, 2025, the company has established a diversified pipeline of nine innovative drugs, with two in commercialization, four in clinical stages, and three in preclinical stages. In addition to its innovative drug pipeline, the company also has a generic drug segment, with three drugs in or nearing commercialization. Currently, VIGONVITA-B's two core products are LV232 and TPN171.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Movement | VIGONVITA-B (02630) Surges Over 15% in Afternoon Trading After Licensing Agreement with SIMCERE PHARMA for VV116 New Indications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Movement | VIGONVITA-B (02630) Surges Over 15% in Afternoon Trading After Licensing Agreement with SIMCERE PHARMA for VV116 New Indications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-17 13:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VIGONVITA-B (02630) surged more than 15% in afternoon trading, rising 14.81% to HK$88 by the time of writing, with a turnover of HK$13.33 million. The company recently announced a licensing agreement with SIMCERE PHARMA (02096) for new indications of VV116. Under the agreement, SIMCERE PHARMA will obtain exclusive licensing rights for deuterium remdesivir hydrobromide dry suspension in Greater China for treating respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections. The collaboration leverages the strengths of both companies in R&D, production, and commercialization to accelerate the clinical development and commercialization of VV116, aiming to benefit more patients. Public data shows that VIGONVITA-B focuses on three therapeutic areas: neuropsychiatry, reproductive health, and viral infections. As of October 21, 2025, the company has established a diversified pipeline of nine innovative drugs, with two in commercialization, four in clinical stages, and three in preclinical stages. In addition to its innovative drug pipeline, the company also has a generic drug segment, with three drugs in or nearing commercialization. Currently, VIGONVITA-B's two core products are LV232 and TPN171.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1183973139","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183973139","pubTimestamp":1765950500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VIGONVITA-B (02630) surged more than 15% in afternoon trading, rising 14.81% to HK$88 by the time of writing, with a turnover of HK$13.33 million. The company recently announced a licensing agreement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业","BK1191":"制药","02630":"旺山旺水-B","BK1583":"高瓴概念"},"translate_title":"港股动向|VIGONVITA-B(02630)与先声药业达成VV116新适应症许可协议后午盘大涨超15%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1,"02630":1},"content_text":"VIGONVITA-B (02630) surged more than 15% in afternoon trading, rising 14.81% to HK$88 by the time of writing, with a turnover of HK$13.33 million. The company recently announced a licensing agreement with SIMCERE PHARMA (02096) for new indications of VV116. Under the agreement, SIMCERE PHARMA will obtain exclusive licensing rights for deuterium remdesivir hydrobromide dry suspension in Greater China for treating respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections. The collaboration leverages the strengths of both companies in R&D, production, and commercialization to accelerate the clinical development and commercialization of VV116, aiming to benefit more patients. Public data shows that VIGONVITA-B focuses on three therapeutic areas: neuropsychiatry, reproductive health, and viral infections. As of October 21, 2025, the company has established a diversified pipeline of nine innovative drugs, with two in commercialization, four in clinical stages, and three in preclinical stages. In addition to its innovative drug pipeline, the company also has a generic drug segment, with three drugs in or nearing commercialization. Currently, VIGONVITA-B's two core products are LV232 and TPN171.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183973139","isCrawlerRequest":true}